ArticleScientific reports2025
Efficacy and safety assessment of gelatin hemostatic matrix in a burr hole neurosurgical beagle model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Absorbable topical hemostatic agents are indispensable for managing excessive bleeding during neurosurgical and emergency procedures, significantly reducing the risk of serious complications. In the current study, we evaluated the hemostatic efficacy of two commercialized hemostatic agents, SURGIFLO (Ethicon, Johnson & Johnson, USA) and Borayerflo (Jiangxi Borayer Biotechnology Ltd, China), in a cerebral hemorrhage model using Beagle dogs. As a result, both SURGIFLO and Borayerflo achieved 100% hemostasis within 5 min of treatment, with no statistically significant differences observed between the two groups. Additionally, blood test results, including fibrinogen (FIB) level, thrombin time (TT), prothrombin time (PT), International Normalized Ratio (INR), and activated partial thromboplastin time (APTT), demonstrated that both SURGIFLO and Borayerflo matrices exhibited excellent blood compatibility and did not interfere with fibrinogen's role in coagulation. Furthermore, toxicity test results indicated that no adverse reactions were observed post-operatively, confirming the safety of both SURGIFLO and Borayerflo. Consequently, the study validates the comparable safety and efficacy of the Borayerflo to SURGIFLO in terms of preclinical hemostatic efficacy and safety, making it a potential alternative product as a suitable absorbable topical hemostatic agent in the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.